Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Diabetes Care

• Publication date

  2006-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.29.03.06.DC05-01467PMID 16505510
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• University of Ostrava Institute for Research and Applications of Fuzzy Modeling Logical Structure of Fuzzy IF-THEN Rules

  2005cited by this paper
• PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel

  2005cited by this paper
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

  2005cited by this paper
• Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

  2004cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• The vasodilatory actions of insulin on resistance and terminal arterioles and their impact on muscle glucose uptake

  2004cited by this paper
• In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.

  2004cited by this paper
• Rosiglitazone Improves, While Glibenclamide Worsens Blood Pressure Control in Treated Hypertensive Diabetic and Dyslipidemic Subjects via Modulation of Insulin Resistance and Sympathetic Activity

  2004cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: a consensus statement from the American Heart Association and American Diabetes Association Response to Nesto

  2004cited by this paper
• Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

  2004cited by this paper
• Insulin sensitivity of muscle capillary recruitment in vivo.

  2004cited by this paper
• Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

  2004cited by this paper
• Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.

  2003cited by this paper
• Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

  2003cited by this paper
• PPARγ activation enhances cell surface ENaCα via up‐regulation of SGK1 in human collecting duct cells

  2003cited by this paper
• Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Rosiglitazone reduces urinary albumin excretion in type II diabetes

  2003cited by this paper
• PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells.

  2003cited by this paper
• Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Peroxisome Proliferator–activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein–induced Endothelin-1 Secretion in Endothelial Cells

  2002cited by this paper
• A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

  2002cited by this paper
• Differentiating members of the thiazolidinedione class: a focus on safety

  2002cited by this paper
• Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

  2002cited by this paper
• Hemodynamic and neurohumoral responses to head-up tilt in patients with chronic fatigue syndrome

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by capillary recruitment.

  2001cited by this paper
• Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

  2001cited by this paper
• Transcapillary escape rate of albumin is increased and related to haemodynamic changes in normo-albuminuric type 1 diabetic patients.

  1999cited by this paper
• Troglitazone has no effect on red cell mass or other erythropoietic parameters

  1999cited by this paper
• Microalbuminuria and transcapillary albumin leakage in essential hypertension.

  1999cited by this paper
• Insulin-induced vasodilatation: physiology or pharmacology?

  1998cited by this paper
• Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.

  1998cited by this paper
• Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone

  1998cited by this paper
• Troglitazone Reduces Contraction by Inhibition of Vascular Smooth Muscle Cell Ca2+ Currents and Not Endothelial Nitric Oxide Production

  1997cited by this paper
• Effects of Insulin and the Combination of Insulin Plus Metformin (Glucophage) on Microvascular Reactivity in Control and Diabetic Hamsters

  1997cited by this paper
• Effects of Insulin on Vascular Tone and Sympathetic Nervous System in NIDDM

  1996cited by this paper
• Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?

  1996cited by this paper
• Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus.

  1996cited by this paper
• Urinary albumin excretion rate and 24-h ambulatory blood pressure in NIDDM with microalbuminuria: effects of a monounsaturated-enriched diet

  1995cited by this paper
• Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

  1995cited by this paper
• Nitric oxide release accounts for insulin's vascular effects in humans.

  1994cited by this paper
• Impaired Insulin-Mediated Skeletal Muscle Blood Flow in Patients With NIDDM

  1992cited by this paper
• Effect of catecholamines and insulin on plasma volume and intravascular mass of albumin in man.

  1989cited by this paper
• Assessment of insulin sensitivity in vivo.

  1985cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper
• Albumin transcapillary escape rate and plasma volume during long-term beta-adrenergic blockade in essential hypertension.

  1973cited by this paper
• The measurement of volume changes in human limbs

  1953influential reference

• Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation

  2024cites this paper
• Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial

  2023cites this paper
• Nonglycemic Adverse Effects of Insulin.

  2021cites this paper
• Endothelial Cell–Targeted Deletion of PPARγ Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue

  2019cites this paper
• Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

  2016influential citation
• Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM

  2015cites this paper
• Impact of Incremental Perfusion Loss on Oxygen Transport in a Capillary Network Mathematical Model

  2015cites this paper
• Skeletal Muscle Vascular Function: A Counterbalance of Insulin Action

  2015cites this paper
• Human in vivo studies on the non-glycaemic effects of thiazolidinedione derivatives

  2014cites this paper
• Pioglitazone does not modify ANP levels of type 2 diabetic patients

  2012cites this paper
• Lipocalin 2 is a selective modulator of peroxisome proliferator‐activated receptor‐γ activation and function in lipid homeostasis and energy expenditure

  2011cites this paper
• Preserved Response to Diuretics in Rosiglitazone‐Treated Subjects With Insulin Resistance: A Randomized Double‐Blind Placebo‐Controlled Crossover Study

  2011cites this paper
• Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage

  2010influential citation
• Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease

  2010cites this paper
• Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes.

  2010cites this paper
• Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes

  2010cites this paper
• Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears

  2009cites this paper
• Vascular endothelial growth factor in systemic capillary leak syndrome.

  2009cites this paper
• Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters

  2009cites this paper
• Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.

  2009cites this paper
• Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

  2008cites this paper
• Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure

  2008cites this paper
• Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.

  2008cites this paper
• Antioxidant supplemention in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance.

  2008cites this paper
• Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects.

  2008cites this paper
• Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non‐diabetic patients

  2008cites this paper
• MRI assessment of drug-induced fluid accumulation in humans: validation of the technology.

  2008cites this paper
• Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe Obesity

  2008cites this paper
• Safety issues and prospects for future generations of PPAR modulators.

  2007cites this paper
• Microvascular Permeability in Diabetes and Insulin Resistance

  2007cites this paper
• The inhibitory effect of rosiglitazone on agonist-induced or spontaneous regulation of contractility

  2007cites this paper
• Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes

  2007cites this paper
• Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.

  2007cites this paper
• Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.

  2007cites this paper
• Vascular effects of PPARγ activators – From bench to bedside

  2007cites this paper
• Vascular effects of PPARgamma activators - from bench to bedside.

  2007cites this paper
• Therapeutic Targets Activated Receptors as Transcriptional Nodal Points and − Peroxisome Proliferator

  2007cites this paper
• Thiazolidinediones and their Fluid-Related Adverse Effects

  2007cites this paper
• Thiazolidinedione derivatives in type 2 diabetes mellitus.

  2006cites this paper
• Review Article Peroxisome Proliferator-activated Receptors and the Heart: Lessons from the past and Future Directions

  year unknowncites this paper